The EUFOREA pocket guide for chronic rhinosinusitis

P W Hellings, W J Fokkens, R Orlandi, G F Adriaensen, I Alobid, F M Baroody, L Bjermer, B A Senior, A Cervin, N A Cohen, J Constantinidis, E De Corso, M Desrosiers, Z Diamant, R G Douglas, S Gane, P Gevaert, J K Han, R J Harvey, C HopkinsR C Kern, B N Landis, J T Lee, S E Lee, A Leunig, V J Lund, B Manuel-Sprekelsen, J Mullol, C Philpott, E Prokopakis, S Reitsma, D Ryan, S Salmi, G Scadding, R J Schlosser, A Steinsvik, P V Tomazic, E Van Staeyen, T Van Zele, O Vanderveken, A-S Viskens, D Conti, M Wagenmann

Research output: Contribution to journalLetterpeer-review

Abstract / Description of output

Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.

Original languageEnglish
Early online date12 Dec 2022
Publication statusE-pub ahead of print - 12 Dec 2022


Dive into the research topics of 'The EUFOREA pocket guide for chronic rhinosinusitis'. Together they form a unique fingerprint.

Cite this